Monitoring of inosine monophosphate dehydrogenase activity and expression during the early period of mycophenolate mofetil therapy in de novo renal transplant patients

Drug Metabolism and Pharmacokinetics

Volumn 28, Issue 2, 2013, Pages 109-117

  Molinaro, Mariadelfina ^a   Chiarelli, Laurent R ^b   Biancone, Luigi ^c   Castagneto, Marco ^d   Luigi, Boschiero ^e   Pisani, Francesco ^f   Sabbatini, Massimo ^g   Sandrini, Silvio ^h   Arbustini, Eloisa ^a   Tinelli, Carmine ^a   Regazzi, Mario ⁱ   Schena, Francesco P ^a   Segoloni, Giuseppe P ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c MOLINETTE HOSPITAL   (Italy)

^d CATHOLIC UNIVERSITY   (Italy)

^e UNIVERSITY HOSPITAL OF VERONA   (Italy)

^f San Salvatore Hospital   (Italy)

^g UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^h SPEDALI CIVILI   (Italy)

ⁱ UNIVERSITY OF BARI   (Italy)

Author keywords

IMPDH activity; IMPDH1 2 gene expression; Pharmacodynamics; Pharmacokinetics; Renal transplantation

Indexed keywords

BASILIXIMAB; CYCLOSPORIN A; INOSINATE DEHYDROGENASE; INOSINATE DEHYDROGENASE 1; INOSINATE DEHYDROGENASE 2; MESSENGER RNA; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ANEMIA; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CORRELATION ANALYSIS; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DRUG DOSE REDUCTION; DRUG MONITORING; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; GENE EXPRESSION; GRAFT REJECTION; HALF LIFE TIME; HUMAN; HUMAN CELL; IMPDH1 GENE; IMPDH2 GENE; ITALY; KIDNEY TRANSPLANTATION; LEUKOPENIA; LONGITUDINAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PREDICTION; PROTEIN EXPRESSION; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 84876748372     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-12-RG-048     Document Type: Article

References (41)

1. van Gelder, T.: Mycophenolate blood level monitoring: recent progress. Am. J. Transplant., 9: 1495-1499 (2009).
2. Kuypers, D. R., Le Meur, Y., Cantarovich, M., Tredger, M. J., Tett, S. E., Cattaneo, D., Tönshoff, B., Holt, D. W., Chapman, J. and van Gelder, T.: Transplantation Society (TTS) Consensus Group on TDM of MPA: Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation. Clin. J. Am. Soc. Nephrol., 5: 341-358 (2010).
3. Glander, P., Hambach, P., Braun, K. P., Fritsche, L., Giessing, M., Mai, I., Einecke, G., Waiser, J., Neumayer, H. H. and Budde, K.: Pre-transplant inosine monophosphate dehydrogenase activity is associated with clinical outcome after renal transplantation. Am. J. Transplant., 4: 2045-2051 (2004).
4. Sanquer, S., Breil, M., Baron, C., Dhamane, D., Astier, A. and Lang, P.: Induction of inosine monophosphate dehydrogenase activity after longterm treatment with mycophenolate mofetil. Clin. Pharmacol. Ther., 65: 640-648 (1999).
5. Sanquer, S., Maison, P., Tomkiewicz, C., Macquin-Mavier, I., Legendre, C., Barouki, R. and Lang, P.: Expression of Inosine monophosphate dehydrogenase type I and type II after mycophenolate mofetil treatment: a 2-year follow-up in kydney transplantation. Clin. Pharmacol. Ther., 83: 328-335 (2008).
6. Chiarelli, L. R., Molinaro, M., Libetta, C., Tinelli, C., Cosmai, L., Valentini, G., Dal Canton, A. and Regazzi, M.: Inosine monophosphate dehydrogenase variability in renal transplant patients on long-term mycophenolate mofetil therapy. Br. J. Clin. Pharmacol., 69: 38-50 (2010).
7. Natsumeda, Y., Ohno, S., Kawasaki, H., Konno, Y., Weber, G. and Suzuki, K.: Two distinct cDNAs for human IMP dehydrogenase. J. Biol. Chem., 265: 5292-5295 (1990).
8. Collart, F. R. and Huberman, E.: Cloning and sequence analysis of the human and Chinese hamster inosine-5A-monophosphate dehydrogenase cDNAs. J. Biol. Chem., 263: 15769-15772 (1988).
9. Gu, J. J., Spychala, J. and Mitchell, B. S.: Regulation of the human inosine monophosphate dehydrogenase type I gene. Utilization of alternative promoters. J. Biol. Chem., 272: 4458-4466 (1997).
10. Zimmermann, A. G., Sphycala, J. and Mitchell, B. S.: Characterization of the human inosine-5A-monophosphate dehydrogenase type II gene. J. Biol. Chem., 270: 6808-6814 (1995).
11. Bremer, S., Mandla, R., Vethe, N. T., Rasmussen, I., Rootwelt, H., Line, P. D., Midtvedt, K. and Bergan, S.: Expression of IMPDH1 and IMPDH2 after transplantation and initiation of immunosuppression. Transplantation, 85: 55-61 (2008).
12. Sombogaard, F., Peeters, A. M., Baan, C. C., Mathot, R. A., Quaedackers, M. E., Vulto, A. G., Weimar, W. and van Gelder, T.: Inosine monophosphate dehydrogenase messenger RNA expression is correlated to clinical outcomes in mycophenolate mofetil-treated kidney transplant patients, whereas inosine monophosphate dehydrogenase activity is not. Ther. Drug Monit., 31: 549-556 (2009).
13. Borrows, R., Chusney, G., Loucaidou, M., James, A., Lee, J., Tromp, J. V., Owen, J., Cairns, T., Griffith, M., Hakim, N., McLean, A., Palmer, A., Papalois, V. and Taube, D.: Mycophenolic acid 12-h trough level monitoring in renal transplantation: association with acute rejection and toxicity. Am. J. Transplant., 6: 121-128 (2006).
14. Mourad, M., Malaise, J., Chaib Eddour, D., De Meyer, M., König, J., Schepers, R., Squifflet, J. P. and Wallemacq, P.: Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. Clin. Chem., 47: 88-94 (2001).
15. Kuypers, D. R., de Jonge, H., Naesens, M., de Loor, H., Halewijck, E., Dekens, M. and Vanrenterghem, Y.: Current target ranges of mycophe nolic acid exposure and drug-related adverse events: a 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients. Clin. Ther., 30: 673-683 (2008).
16. Schütz, E., Armstrong, V. W., Shipkova, M., Weber, L., Niedmann, P. D., Lammersdorf, T., Wiesel, M., Mandelbaum, A., Zimmerhackl, L. B., Mehls, O., Tönshoff, B. and Oellerich, M.: Limited sampling strategy for the determination of mycophenolic acid area under the curve in pediatric kidney recipients. German Study Group on MMF Therapy in Pediatric Renal Transplant Recipients. Transplant. Proc., 30: 1182-1184 (1998).
17. Racusen, L. C., Solez, K., Colvin, R. B., Bonsib, S. M., Castro, M. C., Cavallo, T., Croker, B. P., Demetris, A. J., Drachenberg, C. B., Fogo, A. B., Furness, P., Gaber, L. W., Gibson, I. W., Glotz, D., Goldberg, J. C., Grande, J., Halloran, P. F., Hansen, H. E., Hartley, B., Hayry, P. J., Hill, C. M., Hoffman, E. O., Hunsicker, L. G., Lindblad, A. S., Marcussen, N., Mihatsch, M. J., Nadasdy, T., Nickerson, P., Olsen, T. S., Papadimitriou, J. C., Randhawa, P. S., Rayner, D. C., Roberts, I., Rose, S., Rush, D., Salinas-Madrigal, L., Salomon, D. R., Sund, S., Taskinen, E., Trpkov, K. and Yamaguchi, Y.: The Banff97 working classification of renal allograft pathology. Kidney Int., 55: 713-723 (1999).
18. Solez, K., Colvin, R. B., Racusen, L. C., Sis, B., Halloran, P. F., Birk, P. E., Campbell, P. M., Cascalho, M., Collins, A. B., Demetris, A. J., Drachenberg, C. B., Gibson, I. W., Grimm, P. C., Haas, M., Lerut, E., Liapis, H., Mannon, R. B., Marcus, P. B., Mengel, M., Mihatsch, M. J., Nankivell, B. J., Nickeleit, V., Papadimitriou, J. C., Platt, J. L., Randhawa, P., Roberts, I., Salinas-Madriga, L., Salomon, D. R., Seron, D., Sheaff, M. and Weening, J. J.: The Banff'05 Meeting report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy (CAN). Am. J. Transplant., 7: 518-526 (2007).
19. Green, S. and Weiss, G. R.: Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest. New Drugs, 10: 239-253 (1992).
20. Böyum, A.: Isolation of leucocytes from human blood. A two-phase system for removal of red cells with methylcellulose as erythrocyte aggregating agent. Scand. J. Clin. Lab. Invest. Suppl., 97: 9-29 (1968).
21. van Hest, R. M., Mathôt, R. A., Vulto, A. G., Le Meur, Y. and van Gelder, T.: Mycophenolic acid in diabetic renal transplant recipients. Pharmaco-kinetics and application of a limited sampling strategy. Ther. Drug Monit., 26: 620-625 (2004).
22. Glander, P., Hambach, P., Braun, K. P., Bauer, S., Mai, I., Roots, I., Waiser, J., Fritsche, L., Neumayer, H. H. and Budde, K.: Effect of mycophenolate mofetil on IMP dehydrogenase after the first dose and after long-term treatment in renal transplant recipients. Int. J. Clin. Pharmacol. Ther., 41: 470-476 (2003).
23. Fukuda, T., Goebel, J., Thgersen, H., Maseck, D., Cox, S., Logan, B., Sherbotie, J., Seikaly, M. and Vinks, A. A.: Inosine Monophosphate Dehydrogenase (IMPDH) Activity as a Pharmacodynamic Biomarker of Mycophenolic Acid Effects in Pediatric Kidney Transplant Recipients. J. Clin. Pharmacol., 51: 309-320 (2011).
24. Kamar, N., Glander, P., Nolting, J., Böhler, T., Hambach, P., Liefeldt, L., Rostaing, L., Neumayer, H. H. and Budde, K.: Pharmacodynamic evaluation of the first dose of mycophenolate mofetil before kidney transplantation. Clin. J. Am. Soc. Nephrol., 4: 936-942 (2009).
25. -Ct method. Methods, 25: 402-408 (2001).
26. Liang, K. Y. and Zeger, S. L.: Longitudinal data analysis using generalized linear models. Biometrika, 73: 13-22 (1986).
27. Arns, W., Cibrik, D. M., Walker, R. G., Mourad, G., Budde, K., Mueller, E. A. and Vincenti, F.: Therapeutic drug monitoring of mycophenolic acid in solid organ transplant patients treated with mycophenolate mofetil: review of the literature. Transplantation, 82: 1004-1012 (2006).
28. van Gelder, T., Le Meur, Y., Shaw, L. M., Oellerich, M., DeNofrio, D., Holt, C., Holt, D. W., Kaplan, B., Kuypers, D., Meiser, B., Toenshoff, B. and Mamelok, R. D.: Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther. Drug Monit., 28: 145-154 (2006).
29. Le Meur, Y., Büchler, M., Thierry, A., Caillard, S., Villemain, F., Lavaud, S., Etienne, I., Westeel, P. F., Hurault de Ligny, B., Rostaing, L., Thervet, E., Szelag, J. C., Rérolle, J. P., Rousseau, A., Touchard, G. and Marquet, P.: Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am. J. Transplant., 7: 2496-2503 (2007).
30. van Gelder, T., Silva, H. T., de Fijter, J. W., Budde, K., Kuypers, D., Tyden, G., Lohmus, A., Sommerer, C., Hartmann, A., Le Meur, Y., Oellerich, M., Holt, D. W., Tönshoff, B., Keown, P., Campbell, S. and Mamelok, R. D.: Comparing Mycophenolate Mofetil regimens for denovo renal transplant recipients: the fixed-dose concentration-controled trial. Transplantation, 86: 1043-1051 (2008).
31. Kagaya, H., Miura, M., Saito, M., Habuchi, T. and Satoh, S.: Correlation of IMPDH1 gene polymorphisms with subclinical acute rejection and mycophenolic acid exposure parameters on day 28 after renal trans-plantation. Basic Clin. Pharmacol. Toxicol., 107: 631-636 (2010).
32. Naesens, M., Kuypers, D. R., Verbeke, K. and Vanrenterghen, Y.: Multidrug resistance protein 2 genetic polymorphisms influence myco phenolic acid exposure. Transplantation, 82: 1074-1084 (2006).
33. Kuypers, D. R., Naesens, M., Vermeire, S. and Vanrenterghem, Y.: The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients. Clin. Pharmacol. Ther., 78: 351-361 (2005).
34. Staatz, C. E. and Tett, S. E.: Clinical Pharmacokinetics and Pharmaco-dynamics of Mycophenolate in Solid Organ Transplant Recipients. Clin. Pharmacokinet., 46: 13-58 (2007).
35. Glander, P., Hambach, P., Liefeldt, L. and Budde, K.: Inosine 5A monophosphate dehydrogenase activity as a biomarker in the field of transplantation. Clin. Chim. Acta, 413: 1391-1397 (2012).
36. Hale, M. D., Nicholls, A. J. and Bullingham, R. E.: The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin. Pharmacol. Ther., 64: 672-683 (1998).
37. Mudge, D. W., Atcheson, B. A., Taylor, P. J., Pillans, P. I. and Johnson, D. W.: Severe toxicity associated with a markedly elevated mycophenolic acid free fraction in a renal transplant recipient. Ther. Drug Monit., 26: 453-455 (2004).
38. Atcheson, B. A., Taylor, P. J., Kirkpatrick, C. M. J., Duffull, S. B., Mudge, D. W., Pillans, P. I., Johnson, D. W. and Tett, S. E.: Free mycophenolic acid should be monitored in renal transplant recipients with hypoalbuminemia. Ther. Drug Monit., 26: 284-286 (2004).
39. Kaplan, B., Meier-Kriesche, H. U., Friedman, G., Mulgaonkar, S., Gruber, S., Korecka, M., Brayman, K. L. and Shaw, L. M.: The effect of renal insufficiency of mycophenolic acid protein binding. J. Clin. Pharmacol., 39: 715-720 (1999).
40. Löwenberg, M., Stahn, C., Hommes, D. W. and Buttgereit, F.: Novel insights into mechanisms of glucocorticoid action and the development of new glucocorticoid receptor ligands. Steroids, 73: 1025-1029 (2008).
41. Vogel, C. and Marcotte, E. M.: Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat. Rev. Genet., 13: 227-232 (2012).